GSK plc (GLAXF)

OTCMKTS · Delayed Price · Currency is USD
18.76
-0.18 (-0.95%)
Jul 29, 2025, 3:21 PM EDT
-0.95%
Market Cap75.65B
Revenue (ttm)40.74B
Net Income (ttm)4.07B
Shares Outn/a
EPS (ttm)0.98
PE Ratio18.57
Forward PE8.22
Dividend0.80 (4.21%)
Ex-Dividend DateMay 15, 2025
Volume348
Average Volume1,263
Open18.76
Previous Close18.94
Day's Range18.76 - 18.76
52-Week Range15.54 - 22.45
Beta0.27
RSI50.51
Earnings DateJul 28, 2025

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange OTCMKTS
Ticker Symbol GLAXF
Full Company Profile

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP Financial Statements

News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).  Such investors are advised to contact Daniell...

1 day ago - GlobeNewsWire

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE: GSK) on Monday to develop up to 12 medicines . These agreements will add significant value to Hengrui’s globalization strategy and...

1 day ago - Benzinga

FTSE Rises as US-EU Trade Deal Lifts Mood

FTSE opens higher on trade optimism; GSK signs $12bn China deal, STV issues profit warning. The post FTSE Rises as US-EU Trade Deal Lifts Mood appeared first on Investomania .

1 day ago - Investomania

GSK Enters $12 Billion Collaboration with Hengrui Pharma

GSK Enters $12 Billion Collaboration with Hengrui Pharma

1 day ago - GuruFocus

GSK strikes $12.5B licensing deal with Hengrui Pharma

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

1 day ago - Seeking Alpha

GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects

GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China’s research labs are snapping up mar...

1 day ago - South China Morning Post

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across ...

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology | GSK Stock News

1 day ago - GuruFocus

Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 m...

1 day ago - Reuters

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK fo...

1 day ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Pe...

2 days ago - PRNewsWire

GSK's blood cancer drug gets EU approval for multiple myeloma

British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.

5 days ago - Reuters

Companies Reporting: GSK, Shell, IAG

GSK, Shell and IAG are amongst the FTSE 350 and other companies reporting earnings for the week of 28 July

5 days ago - The Armchair Trader

GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data

The US Food and Drug Administration (FDA) on Wednesday extended the review period for the Biologics License Application (BLA) for GSK plc’s (NYSE: GSK) Blenrep combinations for relapsed or refractory...

5 days ago - Benzinga

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults.

5 days ago - Business Wire

US FDA extends review of GSK's blood cancer drug

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.

6 days ago - Reuters

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).  Such investors are advised to contact Daniell...

6 days ago - GlobeNewsWire

European Stocks Post Small Weekly Drop; GSK Weighs on Healthcare

European stocks ended the week with a small decline, as GSK Plc’s shares weighed on the healthcare sector on a busy earnings day.

11 days ago - Financial Post

Global Stocks Recap: Alibaba, Saab, Burberry, GSK

11 days ago - The Wall Street Journal

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

11 days ago - WSJ

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

FDA panel rejects GSK's Blenrep combo due to ... Full story available on Benzinga.com

11 days ago - Benzinga

GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive

GSK shares sink after FDA panel rejects Blenrep cancer drug, raising doubts over turnaround strategy. The post GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive appeared first on Investo...

11 days ago - Investomania

FTSE 100 Nears Record, GSK Slumps on FDA Setback

FTSE 100 nears record high as dealmaking cheers London, GSK slides on FDA Blenrep blow. The post FTSE 100 Nears Record, GSK Slumps on FDA Setback appeared first on Investomania .

11 days ago - Investomania